Introduction. Lymph node metastasis is determinant in the prognosis and treatment of endometrioid endometrial cancer (EEC) but the risk–benefit balance of surgical lymph node staging remains controversial. Objective. Describe the pathways associated with lymph node metastases in EEC detected by whole RNA sequencing. Methods. RNA-sequencing was performed on a retrospective series of 30 non-metastatic EEC. N+ and N− patients were matched for tumoral size, tumoral grade and myometrial invasion. Results. Twenty-eight EECs were analyzable (16 N+ and 12 N−). Bioinformatics Unsupervised analysis revealed three patterns of expression, enriched in N+, mix of N+/N− and enriched in N−, respectively. The cluster with only N+ patient overexpressed extra cellular matrix, epithelial to mesenchymal and smooth muscle contraction pathways with respect to the N− profile. Differential expression analysis between N+ and N− was used to generate a 54-genes signature with an 87% accuracy. Conclusion. RNA-expression analysis provides a basis to develop a gene expression-based signature that could pre-operatively predict lymph node invasion.
Background: The management of soft-tissue sarcoma (STS) relies on a multidisciplinary approach involving specialized oncological surgery combined with other adjuvant therapies to achieve optimal local disease control. Purpose and Results: Genomic and transcriptomic pseudocapsules of 20 prospective sarcomas were analyzed and revealed to be correlated with a higher risk of recurrence after surgery. Conclusions: A peritumoral environment that has been remodeled and infiltrated by M2 macrophages, and is less expressive of healthy tissue, would pose a significant risk of relapse and require more aggressive treatment strategies.
Metastatic triple-negative breast cancer (mTNBC) remains a major therapeutic challenge, particularly among older women, who are frequently underrepresented in clinical trials. This study aimed to describe the characteristics, treatment patterns, and prognostic factors for real-world progression-free survival (rwPFS) and overall survival (OS) in older (≥70 years) women with metastatic TNBC (mTNBC) compared to younger women. (40-69 years) METHODS: A retrospective analysis of the UNICANCER ESME cohort was conducted, including 4246 women diagnosed with mTNBC between 2008 and 2021. Patient demographics, tumor characteristics, treatment data, and survival outcomes were collected. Kaplan-Meier survival analysis and Cox proportional hazards models were used to assess OS and rwPFS. Older women (n = 987) presented with less aggressive tumors and were less likely to receive chemotherapy or targeted therapy compared to younger women (n = 3259). Median OS was 13.7 months in older women and 15.8 months in younger women, with no significant difference. Prognostic factors for OS and rwPFS included the number of metastatic sites, visceral metastasis, and metastasis-free interval, regardless of age. In older women, age over 80 was associated with poorer prognosis. Despite differences in treatment patterns, survival outcomes were comparable between older and younger women with mTNBC. This real-world analysis underscores the importance of studying mTNBC in older populations, who are often excluded from clinical trials. Further research is needed to optimize treatment strategies for older women with mTNBC, especially with the introduction of new therapies and considering the real world data that allows for a better understanding of this population.